Sentences with phrase «cancer vaccines targeting»

Another possible application for the new machine is generating peptides that could be used as personalized cancer vaccines targeting unique proteins found in individual patients» tumors.

Being both tumor - specific and widely expressed in human tumors, MAGE - A3 is an ideal cancer vaccine target and will be the focus of many clinical trials, including the largest clinical trial ever conducted in lung cancer, MAGRIT, launched by GlaxoSmithKline in 2007.

Not exact matches

His work indicates that this cell surface marker could serve as a target for a novel brain cancer vaccine or T - cell therapies engineered to recognize and kill tumors carrying that neoantigen.

As researchers learn more about genetic profile of various cancers, other work is charging ahead to deliver personalized vaccines targeted to a patient's own tumor cells

By dissecting the heritage of these cells, we can find new targets to tackle a range of conditions including infectious diseases, cancers and immune disorders, and even make vaccines more effective.»

Scientists developed an improved vaccine called 9vHPV that targets HPV 16, 18, 6, and 11, and an additional 5 HPV types that are the next most commonly associated with cervical cancer (HPV 31, 33, 45, 52 and 58).

«The microgravity environment of the International Space Station is now being used for myriad lines of research, for example: vaccine development, finding novel molecular targets against drug - resistant pathogens, and testing of molecules to be used against osteoporosis or cancer,» Zea says.

The Cancer Vaccine Collaborative is working on treatments that target multiple cancer antigens, which should trigger a more aggressive immune response and increase the odds of defeating tCancer Vaccine Collaborative is working on treatments that target multiple cancer antigens, which should trigger a more aggressive immune response and increase the odds of defeating tcancer antigens, which should trigger a more aggressive immune response and increase the odds of defeating tumors.

Researchers used IL - 15 to develop a whole tumor cell vaccine to target breast (TS / A) and prostate (TRAMP - C2) cancer cells in animal models; results showed that tumor cells stopped growing after the vaccine was introduced and that beneficial effects were enhanced further when IL - 15Rα was co-produced by the vaccine cells.

In addition to targeting infectious diseases, the researchers are using this approach to create cancer vaccines that would teach the immune system to recognize and destroy tumors.

Cincinnati Cancer Center (CCC) and UC Cancer Institute researchers have found that a vaccine, targeting tumors that produce a certain protein and receptor responsible for communication between cells and the body's immune system, could initiate the immune response to fight cCancer Center (CCC) and UC Cancer Institute researchers have found that a vaccine, targeting tumors that produce a certain protein and receptor responsible for communication between cells and the body's immune system, could initiate the immune response to fight cCancer Institute researchers have found that a vaccine, targeting tumors that produce a certain protein and receptor responsible for communication between cells and the body's immune system, could initiate the immune response to fight cancercancer.

They created a few different vaccines, targeting HIV, melanoma, and cervical cancer, and tested them in mice.

Scientists are also breaking ground with nucleic acid platforms that have the potential to deliver cancer vaccines, for neoantigens and other targets.

«The key to taking cancer vaccines to another level is combining them with immunotherapies that target the tumor microenvironment,» Kwak said.

By identifying novel biological pathways and publishing details of these interactions, the study team aims to help uncover useful targets in developing better vaccines and cancer treatments.

To that end, Li and his colleagues developed a vaccine that specifically targets cancer stem cells.

Whereas earlier, unsuccessful cancer vaccines usually targeted a single distinctive cancer protein shared among patients, these new ones contain multiple mutated proteins, or «neoantigens,» that are specific to an individual patient's tumor.

A vaccine that targets cancer stem cells dramatically limits tumor growth in mice, researchers reported in April.

One treatment is a vaccine that targets a structure on the outside of cancer cells, while the other is an altered enzyme that breaks apart RNA and causes the cell to commit suicide.

A personal cancer treatment vaccine that targets distinctive «neoantigens» on tumor cells has been shown to stimulate a potent, safe, and highly specific immune anti-tumor response in melanoma patients, report scientists from Dana - Farber Cancer Institute and the Broad Institute of MIT and Hacancer treatment vaccine that targets distinctive «neoantigens» on tumor cells has been shown to stimulate a potent, safe, and highly specific immune anti-tumor response in melanoma patients, report scientists from Dana - Farber Cancer Institute and the Broad Institute of MIT and HaCancer Institute and the Broad Institute of MIT and Harvard.

To meet this end, CCIR members take advantage of resources offered by MD Anderson, including the CCSG Shared Resources, Immune Monitoring Core Laboratory and GMP Cell Facility, allowing them to follow the «bench - to - beside» approach to develop and improve cancer immunotherapy in the form of cellular therapy, a vaccine or targeting antibody, either alone or in combination with conventional therapies or newly developed therapies.

Researchers are studying how to use tumour - specific neoantigens in vaccines to help the body mount an immune response targeted at the cancer.

Because of this unique talent, DCs are now a major focus of laboratory and clinical study across the globe, and are critical targets in cancer vaccine development.

We are developing dendritic cell - based vaccines targeting telomerase, a protein expressed in over 95 percent of cancers and rarely found in normal adult cells.

These are more specific therapies such as monoclonal antibodies and cancer vaccines, which target specific tumor antigens.

As a member of the Vaccine & Immunotherapy Center he studied accelerated vaccine development and targeted cancer therapies until FebruarVaccine & Immunotherapy Center he studied accelerated vaccine development and targeted cancer therapies until Februarvaccine development and targeted cancer therapies until February 2015.

Farokhzad and colleagues have considerable expertise with bench - to - bedside translation of nanotechnologies for medical applications, and foundational work done in part by his team has led to the development and first in human testing of a targeted nanoparticle capable of controlling drug release for treatment of cancers, and the first in human testing of a targeted nanoparticle vaccine capable of orchestrating an immune response to facilitate smoking cessation and relapse prevention.

The high expression frequency of NY - ESO - 1 indicates this as a feasible vaccine target in esophageal cancer.

My studies of cancer genomes have led to characterization of multiple pediatric and adult tumor types, to development of methods that identify and characterize changes in genomic heterogeneity, to defining acquired resistance mechanisms to targeted therapies and to designing novel, personalized vaccines for individual patients.

NJTV - New Pancreatic Study May Offer Hope for the Future - November 17, 2011 CINJ Deputy Director Dr. Edmund Lattime and Co-Director of CINJ's Gastrointestinal - Hepatobiliary Oncology Program Dr. Elizabeth Poplin discuss early results to a unique clinical trial that uses vaccine therapy to target pancreatic cancer.

Telomerase is being explored as a target for therapeutic cancer vaccines.

Turnstone's therapeutic platform is a first - in - class, tumor - targeted oncolytic vaccine that combines potent tumor - killing effects of oncolytic viruses with the benefits of a cancer vaccine that harnesses the patient's own immune system to fight disease in a sustainable manner.

Poznansky adds that the tumors that might be treated with the mesothelin - targeting vaccine — ovarian cancer, pancreatic cancer and mesothelioma — all have poor survival rates.

«We have created a potentially much less expensive approach to making a therapeutic cancer vaccine that, while targeting a single tumor antigen, generates an immune response against multiple antigens.

Physicians with the Personalized Medicine Program at The Tisch Cancer Institute have initiated a phase I proof - of - concept study, a fully personalized multipeptide therapeutic vaccine designed to target tumor - derived neoantigens for individual patients.